Wall Street brokerages expect that Teladoc Health Inc (NYSE:TDOC) will post ($0.36) earnings per share for the current quarter, according to Zacks Investment Research. Eleven analysts have provided estimates for Teladoc Health’s earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.41). Teladoc Health posted earnings of ($0.55) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 34.5%. The firm is expected to issue its next earnings results on Wednesday, November 7th.

On average, analysts expect that Teladoc Health will report full year earnings of ($1.49) per share for the current financial year, with EPS estimates ranging from ($1.57) to ($1.42). For the next financial year, analysts expect that the business will report earnings of ($1.10) per share, with EPS estimates ranging from ($1.56) to ($0.29). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Teladoc Health.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.01. The firm had revenue of $94.60 million during the quarter, compared to analyst estimates of $91.56 million. Teladoc Health had a negative return on equity of 19.10% and a negative net margin of 37.78%. The business’s quarterly revenue was up 112.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.28) earnings per share.

TDOC has been the subject of several research analyst reports. Berenberg Bank initiated coverage on Teladoc Health in a research note on Monday, July 9th. They set a “buy” rating and a $72.00 price target for the company. KeyCorp upped their price target on Teladoc Health from $50.00 to $70.00 and gave the stock an “overweight” rating in a research note on Monday, July 9th. Jefferies Financial Group set a $74.00 price target on Teladoc Health and gave the stock a “buy” rating in a research note on Wednesday, July 11th. Citigroup upped their price target on Teladoc Health to $80.00 and gave the stock a “buy” rating in a research note on Thursday, July 19th. Finally, Canaccord Genuity restated a “buy” rating and set a $70.00 price target (up from $63.00) on shares of Teladoc Health in a research note on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Teladoc Health has an average rating of “Buy” and an average price target of $79.78.

Teladoc Health stock traded down $2.24 during trading on Friday, hitting $75.83. The company’s stock had a trading volume of 2,187,310 shares, compared to its average volume of 1,223,286. The firm has a market capitalization of $6.01 billion, a P/E ratio of -45.96 and a beta of 0.57. The company has a current ratio of 3.14, a quick ratio of 3.14 and a debt-to-equity ratio of 0.58. Teladoc Health has a 1-year low of $27.30 and a 1-year high of $89.05.

In other news, VP Mark Hirschhorn sold 35,000 shares of the stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $80.42, for a total value of $2,814,700.00. Following the completion of the sale, the vice president now owns 10,000 shares in the company, valued at $804,200. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Stephany Verstraete sold 18,000 shares of the stock in a transaction dated Thursday, September 20th. The shares were sold at an average price of $74.79, for a total value of $1,346,220.00. Following the completion of the transaction, the insider now directly owns 13,925 shares of the company’s stock, valued at approximately $1,041,450.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 307,960 shares of company stock valued at $21,422,925. Insiders own 3.95% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of TDOC. Bank of America Corp DE boosted its holdings in Teladoc Health by 82.8% in the second quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after purchasing an additional 853,076 shares during the last quarter. Summit Partners L P purchased a new position in Teladoc Health in the second quarter valued at about $37,772,000. Westwood Management Corp IL boosted its holdings in Teladoc Health by 1,342.6% in the second quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock valued at $34,000,000 after purchasing an additional 545,100 shares during the last quarter. BlackRock Inc. boosted its holdings in Teladoc Health by 9.0% in the second quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock valued at $308,759,000 after purchasing an additional 437,136 shares during the last quarter. Finally, OppenheimerFunds Inc. purchased a new position in Teladoc Health in the second quarter valued at about $20,163,000.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: What is Compound Annual Growth Rate (CAGR)?

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.